Ngā hua rapu - Rohit Loomba

Whakamahine hua
  1. 1
    Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions

    Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions mā Rohit Loomba

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers

    Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers mā Mazen Noureddin, Rohit Loomba

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH

    The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH mā Rohit Loomba, Naga Chalasani

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

    Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease mā Amir Zarrinpar, Rohit Loomba

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions

    Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions mā Rohit Loomba, T. Jake Liang

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications

    Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications mā Saumya Jayakumar, Rohit Loomba

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    PNPLA3 Genotype and Risk of Liver and All‐Cause Mortality

    PNPLA3 Genotype and Risk of Liver and All‐Cause Mortality mā Stefan Stender, Rohit Loomba

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Imaging biomarkers of NAFLD, NASH, and fibrosis

    Imaging biomarkers of NAFLD, NASH, and fibrosis mā Veeral Ajmera, Rohit Loomba

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Advances in the genetics of nonalcoholic fatty liver disease

    Advances in the genetics of nonalcoholic fatty liver disease mā Veeral Ajmera, Rohit Loomba

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

    Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis mā Erin K. Spengler, Rohit Loomba

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD

    Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD mā Elliot B. Tapper, Rohit Loomba

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

    The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH mā Rohit Loomba, Leon A. Adams

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Advances in non-invasive assessment of hepatic fibrosis

    Advances in non-invasive assessment of hepatic fibrosis mā Rohit Loomba, Leon A. Adams

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC

    Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC mā Suzanne R. Sharpton, Rohit Loomba

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Targeting Dysbiosis for the Treatment of Liver Disease

    Targeting Dysbiosis for the Treatment of Liver Disease mā Gobind Anand, Amir Zarrinpar, Rohit Loomba

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease

    Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease mā Michelle T. Long, Sanil Gandhi, Rohit Loomba

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

    The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk mā Cyrielle Caussy, Adrien Aubin, Rohit Loomba

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD

    Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD mā Nobuharu Tamaki, Veeral Ajmera, Rohit Loomba

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease

    Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease mā Rohit Loomba, Vincent Wai‐Sun Wong

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study

    Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study mā Rohit Loomba, Ricki Bettencourt, E. Barrett-Connor

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: